Piper Jaffray Comments On Simcere Pharmaceutical Following Earnings Report

Piper reduced its sales and operating income projections for 2011, but increased net income projection due to a reversal in minority interests. Piper maintains a Neutral rating for now, as it believe lack of guidance from the company has led to a wide variation of analysts' estimates and the difficulty of modeling minority interests makes it difficult to gauge Street expectations for 2011.

Piper Jaffray has a $10 PT and Neutral rating on SCR

SCR closed Monday at $12.49

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.